Skip to main content
SpringerLink
Log in
Book cover

Antioxidants and Cardiovascular Disease pp 255–277Cite as

Synthetic Antioxidants and Atherosclerosis: Human Studies

  • Chapter

  • 960 Accesses

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 258))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aboderin I, Kalache A, Ben-Shlomo Y, et al. Life course perspectives on coronary heart disease, stroke and diabetes: key issues and implications for policy and research. Geneva, World Health Organization, 2002.

    Google Scholar 

  2. American Heart Association. Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2000.

    Google Scholar 

  3. Ross R. Atherosclerosis-An inflammatory disease. N Engl J Med 1999;340:115–26.

    PubMed  CAS  Google Scholar 

  4. Libby P. Changing concepts of atherogenesis. J Intern Med 2000;247:349–58.

    PubMed  CAS  Google Scholar 

  5. Offerman MK, Medford RM. Antioxidants and atherosclerosis: a molecular perspective, Heart Dis Stroke 1994;3:52–7.

    Google Scholar 

  6. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753–66.

    PubMed  CAS  Google Scholar 

  7. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenecity. N Engl J Med 1989;320:915–24.

    PubMed  CAS  Google Scholar 

  8. Witztum JL. The oxidative hypothesis of atherosclerosis. Lancet 1994;344:793–5.

    PubMed  CAS  Google Scholar 

  9. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation 2003;108:1912–6.

    Google Scholar 

  10. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 2003;108:2034–40.

    PubMed  Google Scholar 

  11. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.

    Google Scholar 

  12. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–5.

    PubMed  CAS  Google Scholar 

  13. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.

    PubMed  CAS  Google Scholar 

  14. Gruppo Italiano per lo Studio della Sopravivenza nell’Infarcto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447–55.

    Google Scholar 

  15. The HOPE study investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154–60.

    Google Scholar 

  16. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience Eur Heart J 1999;20:725–41.

    Google Scholar 

  17. Larose E, Tardif JC, Bourassa MG. Use of ACE inhibitors for secondary prevention. Current Treatment Opinions in Cardiovasc Med 2003;5:51–61.

    Google Scholar 

  18. GISSI-3 Collaborators. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115–22.

    Google Scholar 

  19. ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–85.

    Google Scholar 

  20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and left ventricular enlargement trial. N Engl J Med 1992;327:669–77.

    PubMed  CAS  Google Scholar 

  21. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670–6.

    PubMed  CAS  Google Scholar 

  22. The Heart Outcome Prevention Evaluation Study Investigators. Effects of an ACEI, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145–53.

    Google Scholar 

  23. HOPE Investigators. Effects of ramipril on CV and microvascular outcomes in people with DM: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253–8.

    Google Scholar 

  24. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–8.

    Google Scholar 

  25. The PEACE Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058–68.

    Google Scholar 

  26. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.

    Google Scholar 

  27. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071–80.

    PubMed  CAS  Google Scholar 

  28. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504.

    PubMed  CAS  Google Scholar 

  29. Topol EJ. Intensive statin therapy — A sea change in cardiovascular prevention. N Engl J Med 2004;350:1562–4.

    PubMed  CAS  Google Scholar 

  30. Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J 2003;24:225–48.

    PubMed  CAS  Google Scholar 

  31. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335–71.

    PubMed  CAS  Google Scholar 

  32. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in chronic heart failure. N Engl J Med 1996;334:1349–55.

    PubMed  CAS  Google Scholar 

  33. Packer M, Coats AJS, Fowler M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1668–75.

    Google Scholar 

  34. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7.

    Google Scholar 

  35. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial. Lancet 1999;353:9–13.

    Google Scholar 

  36. Brophy JM, Joseph L, Rouleau JL. β-blockers in congestive heart failure: a Bayesian meta-analysis. Ann Intern Med 2001;134:550–60.

    PubMed  CAS  Google Scholar 

  37. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized, controlled trial. Lancet 2003;362:7–13.

    PubMed  CAS  Google Scholar 

  38. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503–10.

    PubMed  CAS  Google Scholar 

  39. Mancini GB, Miller ME, Evans GW, et al. Post hoc analysis of coronary findings from the Prospective Randomized Evaluation of the Vascular Effects of the Norvasc Trial (PREVENT). Am J Cardiol 2002;89:1414–6.

    PubMed  Google Scholar 

  40. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Am Coll Cardiol 2000;35:592–9.

    PubMed  CAS  Google Scholar 

  41. Nissen SE, Tuzcu EM, Libby P, et al. Effects of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004;292:2217–26.

    PubMed  CAS  Google Scholar 

  42. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet 2004;364:849–57.

    PubMed  CAS  Google Scholar 

  43. Waldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: the. Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875–83.

    Google Scholar 

  44. Johansson J, Olsson AG, Bergstrand L, et al. Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report. Arterioscler Thromb Vasc Biol 1995;15:1049–56.

    PubMed  CAS  Google Scholar 

  45. Sawayama Y, Shinizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. J Am Coll Cardiol 2002;39:610–6.

    PubMed  CAS  Google Scholar 

  46. Tardif JC, Coté G, Lespérance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365–72.

    PubMed  CAS  Google Scholar 

  47. Rodes J, Tardif JC, Lespérance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998;97:429–36.

    PubMed  CAS  Google Scholar 

  48. Coté G, Tardif JC, Lespérance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999;99:30–5.

    PubMed  Google Scholar 

  49. Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552–8.

    PubMed  CAS  Google Scholar 

  50. Tardif JC. Clinical results with AGI-1067: a novel antioxidant vascular protectant. Am J Cardiol 2003;91(suppl.):41A–49A.

    PubMed  Google Scholar 

  51. Tardif JC. The future of intravascular ultrasound in the detection and management of coronary artery disease. Can J Cardiol 2000;16(Suppl.D):12D–15D.

    PubMed  Google Scholar 

  52. Tardif JC. Insights into oxidative stress and atherosclerosis. Can J Cardiol 2000;16(Suppl.D):2D–4D.

    PubMed  Google Scholar 

  53. De Keulenaer GW, Ushio-Fukai M, Yin Q, et al. Convergence of redox-sensitive and mitogen-activated protein kinase signaling pathways in tumour necrosis factor-alpha-mediated monocyte chemoattractant protein-1 induction in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:385–91.

    PubMed  Google Scholar 

  54. Marui N, Offerman MK, Swerlick R, et al. Vascular cell adhesion molecule (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866–74.

    PubMed  CAS  Google Scholar 

  55. Fruebis J, Gonzales V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL-receptor-deficient rabbits during early atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1289–302.

    PubMed  CAS  Google Scholar 

  56. Salonen JT, Yla-Herttuala S, Yamamoto R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992;339:883–7.

    PubMed  CAS  Google Scholar 

  57. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134–38.

    PubMed  CAS  Google Scholar 

  58. Rajavashisth TB, Andalibi A, Territo, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins. Nature 1990;344:254–7.

    PubMed  CAS  Google Scholar 

  59. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997;272:15817–24.

    PubMed  CAS  Google Scholar 

  60. Thomas CE, Jackson RL, Ohlweiler DF, et al. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994;35:417–27.

    PubMed  CAS  Google Scholar 

  61. Rajapopalan S, Meng XP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572–9.

    Google Scholar 

  62. Ikeda H, Koga Y, Oda T, et al. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol 1994;24:1749–56.

    PubMed  CAS  Google Scholar 

  63. Li H, Cybulsky MI, Gimbrone MA, Jr., Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulated mononuclear leucocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993;13:197–204.

    PubMed  Google Scholar 

  64. Harrington JR. The role of MCP-1 in atherosclerosis. Stem Cells 2000;18:65–6.

    PubMed  CAS  Google Scholar 

  65. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999;147:213–25.

    PubMed  CAS  Google Scholar 

  66. Gerszten RE, Mach F, Sauty A, Rosenzweig A, Luster Ad. Chemokines, leucocytes, and atherosclerosis. J Lab Clin Med 2000;136:87–92.

    PubMed  CAS  Google Scholar 

  67. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001;107:1255–62.

    PubMed  CAS  Google Scholar 

  68. Davies MJ, Gordon JL, Gearing AJ, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993;171:223–9.

    PubMed  CAS  Google Scholar 

  69. Gerszten RE, Lim YC, Ding HT, et al. Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ Res 1998;82:871–8.

    PubMed  CAS  Google Scholar 

  70. Rohde LE, Lee RT, Rivero J, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1765–70.

    PubMed  CAS  Google Scholar 

  71. De Caterina R, Basta G, Lazzerini G, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646–54.

    PubMed  Google Scholar 

  72. Peter K, Weirich U, Nordt TK, Ruef J, Bode C. Soluble vascular cell adhesion molecule-1 (VCAM-1) as potential marker of atherosclerosis. Thromb Haemost 1999;82(Suppl.1):38–43.

    PubMed  Google Scholar 

  73. Peter K, Nawroth P, Conradt C, et al. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 1997;17:505–12.

    PubMed  CAS  Google Scholar 

  74. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001;104:1336–42.

    PubMed  CAS  Google Scholar 

  75. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation. Part I. Circulation 2003;108:1917–23.

    PubMed  Google Scholar 

  76. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation. Part II. Circulation 2003;108:2041–8.

    PubMed  Google Scholar 

  77. Ridker PM, Rifai N, Rose I, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med2002;347:1557–65.

    CAS  Google Scholar 

  78. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104–11.

    PubMed  CAS  Google Scholar 

  79. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque stability. Circulation 2001;104:1598–603.

    PubMed  CAS  Google Scholar 

  80. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24–30.

    PubMed  CAS  Google Scholar 

  81. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein: when and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341–4.

    PubMed  CAS  Google Scholar 

  82. Keaney JF Jr., Gaziano JM, Xu A, et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994;93:844–51.

    PubMed  Google Scholar 

  83. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583–92.

    PubMed  CAS  Google Scholar 

  84. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141–8.

    PubMed  CAS  Google Scholar 

  85. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001;37:1047–52.

    PubMed  CAS  Google Scholar 

  86. Weiss D, Sorescu D, Taylor WR. Angiotensin II and atherosclerosis. Am J Cardiol 2001;87(suppl.):25C–32C.

    PubMed  CAS  Google Scholar 

  87. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781–91.

    PubMed  CAS  Google Scholar 

  88. Langer A, Constance C, Fodor JG, et al. Statin therapy and the management of acute coronary syndromes. Can J Cardiol 2003;19:921–7.

    PubMed  CAS  Google Scholar 

  89. Saini HK, Arneja AS, Dhalla NS. Role of cholesterol in cardiovascular dysfunction. Can J Cardiol 2004;20:333–46.

    PubMed  CAS  Google Scholar 

  90. Yue TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta adrenoreceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92–8.

    PubMed  CAS  Google Scholar 

  91. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189–93.

    PubMed  CAS  Google Scholar 

  92. Brehm BR, Bertsch D, von Fallois J, Wolf SC. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells. J Cardiovasc Pharmacol 2000;36(suppl. 1):S401–3.

    PubMed  CAS  Google Scholar 

  93. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Asada A. Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med 2004;16:460–5.

    Google Scholar 

  94. Breeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol, a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta (2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677–84.

    Google Scholar 

  95. Cominacini L, Fratta Pasini A, Garbin U, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003;42:1838–44.

    PubMed  CAS  Google Scholar 

  96. de Groot A A, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148–53.

    PubMed  Google Scholar 

  97. Mason RP, Mak IT, Trumbore MW, Mason PE. Antioxidant properties of calcium antagonists related to membrane biophysical interactions. Am J Cardiol 1999;84:16L–22L.

    PubMed  CAS  Google Scholar 

  98. Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R. Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004;70:39–45.

    PubMed  CAS  Google Scholar 

  99. Cominacini L, Pasini AF, Pastorino AM, et al. Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells. J Hypertens 1999;17:1837–41.

    PubMed  CAS  Google Scholar 

  100. Cominacini L, Garbin U, Fratta Pacini A, et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997;15:1633–40.

    PubMed  CAS  Google Scholar 

  101. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990;335:1109–13.

    PubMed  CAS  Google Scholar 

  102. Waters DD, Lesperance J. Interventions that beneficially influence the evolution of coronary atherosclerosis. The case for calcium channel blockers. Circulation 1992;86(Suppl) III:111–6.

    Google Scholar 

  103. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE 1 study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003;107:422–8.

    Google Scholar 

  104. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725–9.

    PubMed  CAS  Google Scholar 

  105. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994;94:155–64.

    PubMed  CAS  Google Scholar 

  106. Wasserman MA, Sundell CL, Kunsch C, et al. Chemistry and pharmacology of vascular protectants. A novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003;91(suppl.):34A–40A.

    PubMed  CAS  Google Scholar 

  107. Meng CQ, Somers PK, Rachita CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002;12:2545–8.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Montreal Heart Institute, Montreal, Quebec, Canada

    Martial G. Bourassa & Jean-Claude Tardif

Authors
  1. Martial G. Bourassa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Claude Tardif
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Montreal Heart Institute Research Center and Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada

    Martial G. Bourassa  & Jean-Claude Tardif  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Bourassa, M.G., Tardif, JC. (2006). Synthetic Antioxidants and Atherosclerosis: Human Studies. In: Bourassa, M.G., Tardif, JC. (eds) Antioxidants and Cardiovascular Disease. Developments in Cardiovascular Medicine, vol 258. Springer, Boston, MA. https://doi.org/10.1007/0-387-29553-4_10

Download citation

  • DOI: https://doi.org/10.1007/0-387-29553-4_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-29552-7

  • Online ISBN: 978-0-387-29553-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation